Biomarker-guided therapy in NSCLC and beyond

Dr. Solange Peters, a renowned medical oncologist specializing in thoracic cancers, presents a detailed case study of a 45-year-old male diagnosed with stage 1B ALK-positive NSCLC during a routine screening. This case study delves into the complexities of diagnostic procedures and the rationale behind choosing specific treatment pathways. This episode underscores the critical role of vigilant monitoring and tailored treatment plans based on comprehensive molecular profiling.

This series of 3 podcasts is accredited for 0.25 AMA Type 1 Credit(s) To learn more about the full program, visit targeted-therapies-lung-cancer.ime.springerhealthcare.com for additional resources, including the webinar and downloadable patient case studies.

This program is made possible thanks to an independent educational grant from Roche and Illumina.

REFERENCES

• Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024;390(14):1265-1276. doi:10.1056/NEJMoa2310532


• Lim JU. Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse. Tuberc Respir Dis (Seoul). 2023 Jan;86(1):14-22. doi: 10.4046/trd.2022.0081. Epub 2022 Oct 26. PMID: 36594192; PMCID: PMC9816492.


• Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056-1064. doi:10.1016/j.annonc.2020.04.478


• Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1-iv21. doi:10.1093/annonc/mdx222